US mRNA specialist Moderna today reported fourth quarter 2025 earnings per share (EPS) of $2.11, $0.51 better than the analyst estimate of $2.62. Revenue for the quarter came in at $678 million versus ...

Full results from the positive Phase III KALOS and LOGOS trials have been published in The Lancet Respiratory Medicine.

Danish CNS specialist Lundbeck has announced positive results from the multiple IV dosing part of PROCEED, an adaptive Phase IIb dose-finding and route of administration trial of bocunebart (Lu ...

US late-stage biotech Immunic, which is developing novel oral therapies for neurologic and gastrointestinal diseases, today ...

German generics and consumer healthcare major STADA Arzneimittel and China’s Bio-Thera Solutions, a commercial-stage ...

USA-based rare disease drug developer PTC Therapeutics saw its shares drop 5.2% to $67.05 after market close, when it announced that it has withdrawn the New Drug Application (NDA) resubmission for ...

Novartis today announced final results from the Phase III ALIGN study supporting a slowing decline in kidney function in adults with IgA nephropathy (IgAN) who were treated with Vanrafia (atrasentan).

At the 44th annual JP Morgan Healthcare conference, US biotech Insmed delivered one of the most closely watched updates in the respiratory space, detailing its clinical and commercial plans for 2026.

US dermatology specialist Verrica Pharmaceuticals has announced the appointment of Chris Chapman as its chief commercial ...

With support from the epidemic preparedness organization CEPI, Serum Institute of India (SII), the world's largest vaccine manufacturer, has entered into a licensing arrangement with the University of ...

Vertex Pharmaceuticals was trading nearly 7% higher by midday Friday, after presenting its fourth quarter and full year 2025 financial results.

Given increasing investor interest in novel, long-acting HIV treatment regimens, Leerink Partners analyst Daina Graybosch has ...